<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378296</url>
  </required_header>
  <id_info>
    <org_study_id>27/2020</org_study_id>
    <secondary_id>PI_20_12CS Telederma</secondary_id>
    <nct_id>NCT04378296</nct_id>
  </id_info>
  <brief_title>Economic Evaluation in Teledermatology</brief_title>
  <acronym>TELEDERMA</acronym>
  <official_title>Economic Evaluation in Dermatology: Teledermatology Versus Conventional Monitoring of Patients in the Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antonio Lopez Villegas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Almeria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Almeria</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Introduction: Previous studies confirm that teledermatology allows the generation of a quick&#xD;
      response from the specialist's consultation, reduction of unnecessary travels, early&#xD;
      diagnosis and priority in the attention to the most urgent cases. Despite these advantages&#xD;
      and that teledermatology has experienced exponential growth since its introduction&#xD;
      approximately 16 years ago in Spain, in Andalusia, its use is still very limited. The&#xD;
      objective of this project will be to carry out an analysis of the quality of life related to&#xD;
      health, costs, cost-utility and informal care of teledermatology services in Primary Care&#xD;
      compared to conventional monitoring carried out at the Hospital de Poniente.&#xD;
&#xD;
      Methodology: A randomized, controlled, unmasked, inter-level clinical trial (Primary&#xD;
      Care-Hospital de Poniente) and multicentre (all health centers attached to the Poniente&#xD;
      Health District of Almería) will be carried out with a 6-month follow-up. Patients will be&#xD;
      assigned to the teledermatology group (experimental) or the conventional monitoring group in&#xD;
      the hospital (control). The patients included in the experimental group will be monitored&#xD;
      asynchronously. Baseline characteristics, number of visits to the hospital, health-related&#xD;
      quality of life, costs, informal care and satisfaction from the perspective of the Andalusian&#xD;
      Public Health System and patients and their caregivers will be analyzed. The generic&#xD;
      EuroQol-5D questionnaire (EQ-5D) will be administered to assess health-related quality of&#xD;
      life and the SKINDEX-29 quality of life dermatological questionnaire. A cost-utility analysis&#xD;
      will be performed to assess whether tele-dermatology is cost-effective in terms of additional&#xD;
      cost for additional quality-adjusted life years (QALYs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EuroQol-5Dimensions questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>From -1 [the poorest imaginable health state] to 1 [perfect health]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical features</measure>
    <time_frame>6 months</time_frame>
    <description>Patient's age; sex; diagnosis; origin; indication (type of dermatological problem); number of visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatological Quality of Life Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>0 (no effect on quality of life) up to 100 (maximum effect on quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare costs</measure>
    <time_frame>6 months</time_frame>
    <description>Costs paid by the Public Health System</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Informal cost</measure>
    <time_frame>6 months</time_frame>
    <description>Costs paid by the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-depth interviews on the healthcare received in Primary Care centers</measure>
    <time_frame>6 months</time_frame>
    <description>1) healthcare center, 2) procedure to make an appointment, 3) medical consultation, 4) nursing consultation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Care Communication Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>The 5-point Likert scale, ranging from 1 (not at all) to 5 (very much).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">442</enrollment>
  <condition>Skin Diseases</condition>
  <arm_group>
    <arm_group_label>Teledermatology</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The 221 patients who are included in this group will be monitored from the Primary Care centers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional monitoring</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The 221 patients included in this group will have to visit the dermatologist at the hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Teledermatology</intervention_name>
    <description>The experimental group will be made up of dermatological patients monitored asynchronously.</description>
    <arm_group_label>Teledermatology</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Be over 18 years old.&#xD;
&#xD;
          -  2. Having any skin disease.&#xD;
&#xD;
          -  3. Accept to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Non-dermatological disease.&#xD;
&#xD;
          -  2. Be participating in another study.&#xD;
&#xD;
          -  3. Refuse to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lopez-Villegas, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Poniente</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Lopez-Villegas, PhD</last_name>
    <phone>+34627238278</phone>
    <email>antoniolopezvillegas@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de Poniente</name>
      <address>
        <city>El Ejido</city>
        <state>Almeria</state>
        <zip>04700</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANTONIO LOPEZ-VILLEGAS, PhD</last_name>
      <phone>34627238278</phone>
      <email>antoniolopezvillegas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonio López-Villegas</name>
      <address>
        <city>El Ejido</city>
        <state>Almería</state>
        <zip>04700</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio L López-Villegas, PhD</last_name>
      <phone>34627238278</phone>
      <email>antoniolopezvillegas@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Almeria</investigator_affiliation>
    <investigator_full_name>Antonio Lopez Villegas</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

